Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study
Cancer · 2025-01 · 131 (1)
DOI: 10.1002/cncr.35681 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 02.01.2025. Verfasst von Melissa Bolier und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Endocrinology Section, Erasmus Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Metabolic Syndrome, Cancer Survivors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stichting Kinderen Kankervrij, KiKaRoW, ODAS Stichting.
Abstract (Originalsprache)
Background
Because the occurrence of metabolic syndrome (MetS) might contribute to childhood cancer survivor’s excess risk of cardiovascular disease, the authors assessed the prevalence and determinants of MetS in the Dutch Childhood Cancer Survivor Study (DCCSS‐LATER2) cohort.
Methods
In total, 2338 adult childhood cancer survivors (CCS) were cross‐sectionally assessed for the prevalence of MetS, using the Lifelines cohort ( N = 132,226 adults without a history of cancer) as references. The prevalence of MetS was clinically assessed using existing classifications, as well as an alternative method using dual‐energy x‐ray absorptiometry fat% instead of waist circumference to define abdominal adiposity. Logistic regression models, adjusted for age and sex, were used to investigate the association between the presence of MetS and both cohorts. Demographic, lifestyle, and treatment determinants of MetS were identified through multivariable logistic regression.
Results
The survivor cohort (median age, 34.7 years, median follow‐up time, 27.1 years) showed increased adjusted odds ratio (aOR) for MetS (modified National Cholesterol Education Program Adult Treatment Panel III criteria), as compared to the reference cohort (aOR, 2.07; 95% confidence interval [CI], 1.85–2.32). Compared to these criteria, the alternative method identified 57 additional survivors with MetS (395 of 2070 [19.1%] vs. 452 of 1960 [23.1%], respectively). Age (odds ratio [OR], 1.07; 95% CI, 1.04–1.10, per year increase), smoking (OR, 1.46; 95% CI, 1.04–2.04), low physical activity (OR, 1.48; 95% CI, 1.05–2.09), abdominal radiotherapy (OR, 2.13; 95% CI, 1.01–4.31; >30 Gy), cranial radiotherapy (OR, 2.89; 95% CI, 1.67–4.96; 1–25 Gy; and OR, 2.44; 95% CI, 1.30–4.47; >25 Gy), total body irradiation (OR, 6.17; 95% CI, 3.20–11.76), and underlying central nervous system tumor (OR, 1.78; 95% CI, 1.21–2.60) were associated with MetS.
Conclusion
The high risk of MetS in CCS, combined with several potential modifiable factors, underscores the need for timely identification and intervention strategies to mitigate the long‐term cardiovascular risks in CCS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Endocrinology Section, Erasmus Medical Center, Rotterdam, The Netherlands.
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- Department of Biomedical Data Science, Medical Statistics Section, Leiden University Medical Center, Leiden, The Netherlands.
- Mathematical Institute Leiden University, Leiden, The Netherlands.
- Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands.
- Pediatric Oncology, Cancer Center Amsterdam, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
ORCID-Profile: Melissa Bolier
Förderung
- Stichting Kinderen Kankervrij
- KiKaRoW
- ODAS Stichting
Zitieren
APA
Bolier, M., de Winter, D. T. C., Pluimakers, V. G., Fiocco, M., van den Berg, S. A. A., Bresters, D., van Dulmen-den Broeder, E., van der Heiden-van der Loo, M., Höfer, I., Janssens, G. O., Kremer, L. C. M., Loonen, J. J., Louwerens, M., van der Pal, H. J., Pluijm, S. M. F., Tissing, W. J. E., van Santen, H. M., de Vries, A. C. H., van der Lely, A. J., …, & Neggers, S. J. C. M. M. (2025). Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study. Cancer, 131(1). https://doi.org/10.1002/cncr.35681
Vancouver
Bolier M, de Winter DTC, Pluimakers VG, Fiocco M, van den Berg SAA, Bresters D, et al. Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study. Cancer. 2025;131(1). doi:10.1002/cncr.35681
BibTeX
@article{Bolier2025,
author = {Bolier, Melissa and de Winter, Demi T C and Pluimakers, Vincent G and Fiocco, Marta and van den Berg, Sjoerd A A and Bresters, Dorine and van Dulmen-den Broeder, Eline and van der Heiden-van der Loo, Margriet and Höfer, Imo and Janssens, Geert O and Kremer, Leontien C M and Loonen, Jacqueline J and Louwerens, Marloes and van der Pal, Heleen J and Pluijm, Saskia M F and Tissing, Wim J E and van Santen, Hanneke M and de Vries, Andrica C H and van der Lely, Aart-Jan and van den Heuvel-Eibrink, Marry M and Neggers, Sebastian J C M M},
title = {Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study},
journal = {Cancer},
year = {2025},
volume = {131},
number = {1},
doi = {10.1002/cncr.35681}
}
EUVIMED